Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

ELV vs DBVT vs UNH vs ALKS vs MCK

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
ELV
Elevance Health Inc.

Medical - Healthcare Plans

HealthcareNYSE • US
Market Cap$80.98B
5Y Perf.+26.8%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1712.35T
5Y Perf.-58.8%
UNH
UnitedHealth Group Incorporated

Medical - Healthcare Plans

HealthcareNYSE • US
Market Cap$335.60B
5Y Perf.+21.3%
ALKS
Alkermes plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$5.90B
5Y Perf.+116.4%
MCK
McKesson Corporation

Medical - Distribution

HealthcareNYSE • US
Market Cap$92.15B
5Y Perf.+374.1%

ELV vs DBVT vs UNH vs ALKS vs MCK — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
ELV logoELV
DBVT logoDBVT
UNH logoUNH
ALKS logoALKS
MCK logoMCK
IndustryMedical - Healthcare PlansBiotechnologyMedical - Healthcare PlansBiotechnologyMedical - Distribution
Market Cap$80.98B$1712.35T$335.60B$5.90B$92.15B
Revenue (TTM)$200.41B$0.00$449.71B$1.56B$403.43B
Net Income (TTM)$5.24B$-168M$12.04B$153M$4.76B
Gross Margin23.2%18.8%65.4%3.6%
Operating Margin3.8%4.2%12.3%1.5%
Forward P/E13.9x20.2x24.8x19.3x
Total Debt$33.23B$22M$78.39B$70M$7.39B
Cash & Equiv.$9.49B$194M$24.36B$1.12B$5.69B

ELV vs DBVT vs UNH vs ALKS vs MCKLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

ELV
DBVT
UNH
ALKS
MCK
StockMay 20May 26Return
Elevance Health Inc. (ELV)100126.8+26.8%
DBV Technologies S.… (DBVT)10041.2-58.8%
UnitedHealth Group … (UNH)100121.3+21.3%
Alkermes plc (ALKS)100216.4+116.4%
McKesson Corporation (MCK)100474.1+374.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: ELV vs DBVT vs UNH vs ALKS vs MCK

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MCK leads in 3 of 7 categories (5-stock set), making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Elevance Health Inc. is the stronger pick specifically for valuation and capital efficiency. DBVT, UNH, and ALKS also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
ELV
Elevance Health Inc.
The Insurance Pick

ELV is the #2 pick in this set and the best alternative if sleep-well-at-night and defensive is your priority.

  • Lower volatility, beta 0.46, Low D/E 75.5%, current ratio 1.24x
  • Beta 0.46, yield 1.8%, current ratio 1.24x
  • Lower P/E (13.9x vs 20.2x)
Best for: sleep-well-at-night and defensive
DBVT
DBV Technologies S.A.
The Momentum Pick

DBVT ranks third and is worth considering specifically for momentum.

  • +110.4% vs ELV's -9.0%
Best for: momentum
UNH
UnitedHealth Group Incorporated
The Insurance Pick

UNH is the clearest fit if your priority is income & stability.

  • Dividend streak 25 yrs, beta 0.59, yield 2.4%
  • 2.4% yield, 25-year raise streak, vs ELV's 1.8%, (2 stocks pay no dividend)
Best for: income & stability
ALKS
Alkermes plc
The Quality Compounder

ALKS is the clearest fit if your priority is quality.

  • 9.8% margin vs DBVT's 0.3%
Best for: quality
MCK
McKesson Corporation
The Growth Play

MCK carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 16.2%, EPS growth 14.9%, 3Y rev CAGR 10.8%
  • 348.1% 10Y total return vs UNH's 220.6%
  • PEG 0.49 vs ELV's 2.01
  • 16.2% revenue growth vs DBVT's -100.0%
Best for: growth exposure and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthMCK logoMCK16.2% revenue growth vs DBVT's -100.0%
ValueELV logoELVLower P/E (13.9x vs 20.2x)
Quality / MarginsALKS logoALKS9.8% margin vs DBVT's 0.3%
Stability / SafetyMCK logoMCKBeta 0.04 vs DBVT's 1.26
DividendsUNH logoUNH2.4% yield, 25-year raise streak, vs ELV's 1.8%, (2 stocks pay no dividend)
Momentum (1Y)DBVT logoDBVT+110.4% vs ELV's -9.0%
Efficiency (ROA)MCK logoMCK5.7% ROA vs DBVT's -89.0%

ELV vs DBVT vs UNH vs ALKS vs MCK — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

ELVElevance Health Inc.
FY 2025
Health Benefits Segment
84.8%$167.1B
Carelon Services Segment
36.4%$71.7B
Segment Eliminations
-21.1%$-41,689,000,000
DBVTDBV Technologies S.A.

Segment breakdown not available.

UNHUnitedHealth Group Incorporated
FY 2025
Unitedhealthcare
94.4%$332.4B
Optumhealth
5.6%$19.8B
ALKSAlkermes plc
FY 2025
Vivitrol
39.8%$468M
Aristada And Aristada Initio
31.5%$370M
Manufactured Product And Royalty
24.8%$291M
Manufacturing Revenue
3.9%$46M
MCKMcKesson Corporation
FY 2025
U.S. Pharmaceutical Segment
91.3%$327.7B
International Segment
4.1%$14.7B
Medical-Surgical Solutions Segment
3.2%$11.4B
Prescription Technology Solutions
1.5%$5.2B

ELV vs DBVT vs UNH vs ALKS vs MCK — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLMCKLAGGINGDBVT

Income & Cash Flow (Last 12 Months)

ALKS leads this category, winning 5 of 6 comparable metrics.

UNH and DBVT operate at a comparable scale, with $449.7B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to MCK's 1.2%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricELV logoELVElevance Health I…DBVT logoDBVTDBV Technologies …UNH logoUNHUnitedHealth Grou…ALKS logoALKSAlkermes plcMCK logoMCKMcKesson Corporat…
RevenueTrailing 12 months$200.4B$0$449.7B$1.6B$403.4B
EBITDAEarnings before interest/tax$8.9B-$112M$23.2B$212M$6.8B
Net IncomeAfter-tax profit$5.2B-$168M$12.0B$153M$4.8B
Free Cash FlowCash after capex$6.5B-$151M$19.7B$392M$6.0B
Gross MarginGross profit ÷ Revenue+23.2%+18.8%+65.4%+3.6%
Operating MarginEBIT ÷ Revenue+3.8%+4.2%+12.3%+1.5%
Net MarginNet income ÷ Revenue+2.6%+2.7%+9.8%+1.2%
FCF MarginFCF ÷ Revenue+3.2%+4.4%+25.1%+1.5%
Rev. Growth (YoY)Latest quarter vs prior year+2.6%+2.0%+28.2%+6.0%
EPS Growth (YoY)Latest quarter vs prior year-16.8%+91.5%+0.7%-4.1%+37.0%
ALKS leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

Evenly matched — ELV and DBVT and MCK each lead in 2 of 7 comparable metrics.

At 14.8x trailing earnings, ELV trades at a 49% valuation discount to MCK's 29.2x P/E. Adjusting for growth (PEG ratio), MCK offers better value at 0.75x vs ELV's 2.15x — a lower PEG means you pay less per unit of expected earnings growth.

MetricELV logoELVElevance Health I…DBVT logoDBVTDBV Technologies …UNH logoUNHUnitedHealth Grou…ALKS logoALKSAlkermes plcMCK logoMCKMcKesson Corporat…
Market CapShares × price$81.0B$1712.35T$335.6B$5.9B$92.1B
Enterprise ValueMkt cap + debt − cash$104.7B$1712.35T$389.6B$4.9B$93.8B
Trailing P/EPrice ÷ TTM EPS14.84x-0.76x27.95x24.76x29.25x
Forward P/EPrice ÷ next-FY EPS est.13.93x20.19x19.28x
PEG RatioP/E ÷ EPS growth rate2.15x0.75x
EV / EBITDAEnterprise value multiple10.84x16.70x17.25x18.74x
Price / SalesMarket cap ÷ Revenue0.41x0.75x4.00x0.26x
Price / BookPrice ÷ Book value/share1.88x0.66x3.31x3.28x
Price / FCFMarket cap ÷ FCF25.51x20.88x12.28x17.63x
Evenly matched — ELV and DBVT and MCK each lead in 2 of 7 comparable metrics.

Profitability & Efficiency

MCK leads this category, winning 5 of 9 comparable metrics.

MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to UNH's 0.77x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs DBVT's 4/9, reflecting strong financial health.

MetricELV logoELVElevance Health I…DBVT logoDBVTDBV Technologies …UNH logoUNHUnitedHealth Grou…ALKS logoALKSAlkermes plcMCK logoMCKMcKesson Corporat…
ROE (TTM)Return on equity+11.9%-130.2%+11.5%+8.8%+3.0%
ROA (TTM)Return on assets+4.3%-89.0%+3.9%+5.4%+5.7%
ROICReturn on invested capital+9.1%+9.2%+18.9%+5.4%
ROCEReturn on capital employed+8.2%-145.7%+9.7%+14.2%+30.5%
Piotroski ScoreFundamental quality 0–964676
Debt / EquityFinancial leverage0.75x0.13x0.77x0.04x
Net DebtTotal debt minus cash$23.7B-$172M$54.0B-$1.0B$1.7B
Cash & Equiv.Liquid assets$9.5B$194M$24.4B$1.1B$5.7B
Total DebtShort + long-term debt$33.2B$22M$78.4B$70M$7.4B
Interest CoverageEBIT ÷ Interest expense5.39x-189.82x4.71x32.30x33.79x
MCK leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

MCK leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, DBVT leads with a +110.4% total return vs ELV's -9.0%. The 3-year compound annual growth rate (CAGR) favors MCK at 27.3% vs UNH's -7.1% — a key indicator of consistent wealth creation.

MetricELV logoELVElevance Health I…DBVT logoDBVTDBV Technologies …UNH logoUNHUnitedHealth Grou…ALKS logoALKSAlkermes plcMCK logoMCKMcKesson Corporat…
YTD ReturnYear-to-date+5.8%+4.9%+10.6%+25.3%-8.5%
1-Year ReturnPast 12 months-9.0%+110.4%-3.2%+16.5%+4.6%
3-Year ReturnCumulative with dividends-15.6%+19.7%-19.9%+14.5%+106.4%
5-Year ReturnCumulative with dividends+1.5%-69.1%-2.6%+60.9%+286.9%
10-Year ReturnCumulative with dividends+202.1%-87.0%+220.6%-11.0%+348.1%
CAGR (3Y)Annualised 3-year return-5.5%+6.2%-7.1%+4.6%+27.3%
MCK leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — ALKS and MCK each lead in 1 of 2 comparable metrics.

MCK is the less volatile stock with a 0.04 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs MCK's 75.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricELV logoELVElevance Health I…DBVT logoDBVTDBV Technologies …UNH logoUNHUnitedHealth Grou…ALKS logoALKSAlkermes plcMCK logoMCKMcKesson Corporat…
Beta (5Y)Sensitivity to S&P 5000.46x1.26x0.59x1.06x0.04x
52-Week HighHighest price in past year$424.24$26.18$395.52$36.60$999.00
52-Week LowLowest price in past year$273.71$7.53$234.60$25.17$637.00
% of 52W HighCurrent price vs 52-week peak+87.9%+76.3%+93.5%+96.7%+75.3%
RSI (14)Momentum oscillator 0–10075.548.175.960.216.2
Avg Volume (50D)Average daily shares traded1.9M252K7.9M2.3M757K
Evenly matched — ALKS and MCK each lead in 1 of 2 comparable metrics.

Analyst Outlook

UNH leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: ELV as "Buy", DBVT as "Buy", UNH as "Buy", ALKS as "Buy", MCK as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 2.5% for ELV (target: $382). For income investors, UNH offers the higher dividend yield at 2.35% vs MCK's 0.36%.

MetricELV logoELVElevance Health I…DBVT logoDBVTDBV Technologies …UNH logoUNHUnitedHealth Grou…ALKS logoALKSAlkermes plcMCK logoMCKMcKesson Corporat…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuyBuy
Price TargetConsensus 12-month target$382.38$46.33$385.43$44.00$1006.50
# AnalystsCovering analysts3715522831
Dividend YieldAnnual dividend ÷ price+1.8%+2.4%+0.4%
Dividend StreakConsecutive years of raises15025017
Dividend / ShareAnnual DPS$6.89$8.70$2.69
Buyback YieldShare repurchases ÷ mkt cap+3.2%0.0%+1.7%+0.5%+3.4%
UNH leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

MCK leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). ALKS leads in 1 (Income & Cash Flow). 2 tied.

Best OverallMcKesson Corporation (MCK)Leads 2 of 6 categories
Loading custom metrics...

ELV vs DBVT vs UNH vs ALKS vs MCK: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is ELV or DBVT or UNH or ALKS or MCK a better buy right now?

For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.

2% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Elevance Health Inc. (ELV) offers the better valuation at 14. 8x trailing P/E (13. 9x forward), making it the more compelling value choice. Analysts rate Elevance Health Inc. (ELV) a "Buy" — based on 37 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — ELV or DBVT or UNH or ALKS or MCK?

On trailing P/E, Elevance Health Inc.

(ELV) is the cheapest at 14. 8x versus McKesson Corporation at 29. 2x. On forward P/E, Elevance Health Inc. is actually cheaper at 13. 9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: McKesson Corporation wins at 0. 49x versus Elevance Health Inc. 's 2. 01x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — ELV or DBVT or UNH or ALKS or MCK?

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.

9%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: MCK returned +348. 1% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — ELV or DBVT or UNH or ALKS or MCK?

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at 0.

04β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 2818% more volatile than MCK relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 77% for UnitedHealth Group Incorporated — giving it more financial flexibility in a downturn.

05

Which is growing faster — ELV or DBVT or UNH or ALKS or MCK?

By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.

2% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: McKesson Corporation grew EPS 14. 9% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, UNH leads at 11. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — ELV or DBVT or UNH or ALKS or MCK?

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is ELV or DBVT or UNH or ALKS or MCK more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, McKesson Corporation (MCK) is the more undervalued stock at a PEG of 0. 49x versus Elevance Health Inc. 's 2. 01x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Elevance Health Inc. (ELV) trades at 13. 9x forward P/E versus 20. 2x for UnitedHealth Group Incorporated — 6. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

08

Which pays a better dividend — ELV or DBVT or UNH or ALKS or MCK?

In this comparison, UNH (2.

4% yield), ELV (1. 8% yield), MCK (0. 4% yield) pay a dividend. DBVT, ALKS do not pay a meaningful dividend and should not be held primarily for income.

09

Is ELV or DBVT or UNH or ALKS or MCK better for a retirement portfolio?

For long-horizon retirement investors, Elevance Health Inc.

(ELV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 46), 1. 8% yield, +202. 1% 10Y return). Both have compounded well over 10 years (ELV: +202. 1%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between ELV and DBVT and UNH and ALKS and MCK?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ELV is a mid-cap deep-value stock; DBVT is a mega-cap quality compounder stock; UNH is a large-cap quality compounder stock; ALKS is a small-cap quality compounder stock; MCK is a mid-cap high-growth stock. ELV, UNH pay a dividend while DBVT, ALKS, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

ELV

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 13%
  • Dividend Yield > 0.7%
Run This Screen
Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

UNH

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Dividend Yield > 0.9%
Run This Screen
Stocks Like

ALKS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

MCK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.